[1].  Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. (2021). Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021 Sep;171:105780. doi: 10.1016/j.phrs.2021.105780. Epub 2021 Jul 21. PMID: 34302977; PMCID: PMC8384724.

[2].  J. L. Shah, G. H. Li, and S. G. Soltys, (2024). “Glioblastoma Multiforme,” CyberKnife Stereotactic Radiosurgery: Brain, vol. 1, pp. 85–98, May 2024, doi: 10.22290/jbnc.v24i1.1481.

[3].  Sipos, D.; Raposa, B.L.; Freihat, O.; Simon, M.; Mekis, N.; Cornacchione, P.; Kovács, Á. (2025). Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers 2025, 17, 146. https://doi.org/10.3390/cancers17010146

[4].  Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I. (2022). Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers (Basel). 2022 May 13;14(10):2412. doi: 10.3390/cancers14102412. PMID: 35626018; PMCID: PMC9139611.

[5].  Alves, A.L.V., Gomes, I.N.F., Carloni, A.C. (2021). Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. Stem Cell Res Ther 12, 206. https://doi.org/10.1186/s13287-021-02231-x

[6].  N. Singh, A. Miner, L. Hennis, and S. Mittal, (2021). “Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review,” Cancer Drug Resistance, vol. 4, no. 1, p. 17, 2021, doi: 10.20517/CDR.2020.79.

[7].  M. Kaya and B. Ahishali, (2020). “Basic physiology of the blood-brain barrier in health and disease: a brief overview,” Tissue Barriers, vol. 9, no. 1, p. 1840913, 2020, doi: 10.1080/21688370.2020.1840913.

[8].  D. Wu, Q. Chen, X. Chen, F. Han, Z. Chen, and Y. Wang, (2023). “The blood–brain barrier: Structure, regulation and drug delivery,” Signal Transduct. Target. Ther., vol. 8, no. 1, p. 217, Dec. 2023, doi: 10.1038/S41392-023-01481-W.

[9].  Luo, Q., Yang, J., Yang, M., Wang, Y., Liu, Y., Liu, J., Kalvakolanu, D. V, Cong, X., Zhang, J., Zhang, L., Guo, B., & Duo, Y. (2025). Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system. Materials Today Bio, 31, 101457. https://doi.org/https://doi.org/10.1016/j.mtbio.2025.101457

[10].       Kochman, U., Sitka, H., Kuźniar, J. (2026). Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review. Mol Neurobiol 63, 75. https://doi.org/10.1007/s12035-025-05417-z

[11].       M. S. Thomsen, K. B. Johnsen, K. Kucharz, M. Lauritzen, and T. Moos, (2022). “Blood–Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles,” Pharmaceutics, vol. 14, no. 10, p. 2237, Oct. 2022, doi: 10.3390/PHARMACEUTICS14102237.

[12].       K. Królikowska, K. Błaszczak, S. Ławicki, M. Zajkowska, and M. Gudowska-Sawczuk, (2025). “Glioblastoma—A Contemporary Overview of Epidemiology, Classification, Pathogenesis, Diagnosis, and Treatment: A Review Article,” Int. J. Mol. Sci., vol. 26, no. 24, p. 12162, Dec. 2025, doi: 10.3390/IJMS262412162.

[13].       Makino R, Higa N, Akahane T, Yonezawa H, Uchida H, Takajo T, Fujio S, Kirishima M, Hamada T, Yamahata H, Kamimura K, Yoshiura T, Yoshimoto K, Tanimoto A, Hanaya R. (2023). Alterations in EGFR and PDGFRA are associated with the localization of contrast-enhancing lesions in glioblastoma. Neurooncol Adv. 2023 Sep 2;5(1):vdad110. doi: 10.1093/noajnl/vdad110. PMID: 37744696; PMCID: PMC10516461.

[14].       Y. Kondo, K. Katsushima, F. Ohka, A. Natsume, and K. Shinjo, (2014). “Epigenetic dysregulation in glioma,” Cancer Sci., vol. 105, no. 4, p. 363, 2014, doi: 10.1111/CAS.12379.

[15].       Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, Mokhtari K, Shahpasand K, Farahani N, Meybodi TE, Entezari M, Taheriazam A, Hushmandi K, Hashemi M. (2025). Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025 Feb 26;24(1):58. doi: 10.1186/s12943-025-02267-0. Erratum in: Mol Cancer. 2026 Jun 26;25(1):156. doi: 10.1186/s12943-026-02717-3. PMID: 40011944; PMCID: PMC11863469.

[16].       S. Keller and M. H. H. Schmidt, (2017). “EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment,” Int. J. Mol. Sci., vol. 18, no. 6, p. 1295, Jun. 2017, doi: 10.3390/IJMS18061295.

[17].       A. Papa and P. P. Pandolfi, (2019). “The PTEN–PI3K Axis in Cancer,” Biomolecules 2019, Vol. 9, Page 153, vol. 9, no. 4, p. 153, Apr. 2019, doi: 10.3390/BIOM9040153.

[18].       Zhang Y, Dube C, Gibert M Jr, Cruickshanks N, Wang B, Coughlan M, Yang Y, Setiady I, Deveau C, Saoud K, Grello C, Oxford M, Yuan F, Abounader R. (2018). The p53 Pathway in Glioblastoma. Cancers (Basel). 2018 Sep 1;10(9):297. doi: 10.3390/cancers10090297. PMID: 30200436; PMCID: PMC6162501.

[19].       C. Guo, C. J. Pirozzi, G. Y. Lopez, and H. Yan, (2011). “Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target,” Curr. Opin. Neurol., vol. 24, no. 6, p. 648, Dec. 2011, doi: 10.1097/WCO.0B013E32834CD415.

[20].       D. Garnier, O. Renoult, M. C. Alves-Guerra, F. Paris, and C. Pecqueur, (2019). “Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target,” Front. Oncol., vol. 9, no. MAR, p. 118, 2019, doi: 10.3389/FONC.2019.00118.

[21].       Y. Tian, L. E. I. Yongrong, Y. Wang, L. A. I. Jiejuan, J. Wang, and X. I. A. Feng, (2023). “Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review),” Int. J. Oncol., vol. 63, no. 5, p. 119, Nov. 2023, doi: 10.3892/IJO.2023.5567.

[22].       Y. Liu, F. Zhou, H. Ali, J. D. Lathia, and P. Chen, (2024). “Immunotherapy for glioblastoma: current state, challenges, and future perspectives,” Cellular & Molecular Immunology 2024 21:12, vol. 21, no. 12, pp. 1354–1375, Oct. 2024, doi: 10.1038/s41423-024-01226-x.

[23].       N. Choudhary, R. C. Osorio, J. Y. Oh, and M. K. Aghi, (2023). “Metabolic Barriers to Glioblastoma Immunotherapy,” Cancers (Basel)., vol. 15, no. 5, p. 1519, Mar. 2023, doi: 10.3390/CANCERS15051519.

[24].       B. K. Ahir, H. H. Engelhard, and S. S. Lakka, (2020). “Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma,” Mol. Neurobiol., vol. 57, no. 5, p. 2461, May 2020, doi: 10.1007/S12035-020-01892-8.

[25].       A. Nowacka, M. Śniegocki, W. Smuczyński, D. Bożiłow, and E. Ziółkowska, (2025). “Angiogenesis in Glioblastoma—Treatment Approaches,” Cells, vol. 14, no. 6, p. 407, Mar. 2025, doi: 10.3390/CELLS14060407.

[26].       Marathe, K., Gupta, D. S., Barve, K., & Bodas, D. (2026). A critical appraisal of drug transport across the blood-brain barrier: Evaluation using new-age microfluidic technique. Brain Research Bulletin, 234, 111662. https://doi.org/https://doi.org/10.1016/j.brainresbull.2025.111662

[27].       D. Wu, Q. Chen, X. Chen, F. Han, Z. Chen, and Y. Wang, (2023). “The blood–brain barrier: structure, regulation, and drug delivery,” Signal Transduct. Target. Ther., vol. 8, no. 1, pp. 217-, Dec. 2023, doi: 10.1038/S41392-023-01481-W;SUBJMETA.

[28].       S. M. Stamatovic, R. F. Keep, and A. V Andjelkovic, (2008). “Brain Endothelial Cell-Cell Junctions: How to ‘Open’ the Blood Brain Barrier,” Curr. Neuropharmacol., vol. 6, no. 3, p. 179, Sep. 2008, doi: 10.2174/157015908785777210.

[29].       M. D. Sweeney, S. Ayyadurai, and B. V. Zlokovic, “Pericytes of the neurovascular unit: Key functions and signaling pathways,” Nat. Neurosci., vol. 19, no. 6, p. 771, Apr. 2016, doi: 10.1038/NN.4288.

[30].       C. Y. Liu, Y. Yang, W. N. Ju, X. Wang, and H. L. Zhang, (2018). “Emerging Roles of Astrocytes in Neuro-Vascular Unit and the Tripartite Synapse With Emphasis on Reactive Gliosis in the Context of Alzheimer’s Disease,” Front. Cell. Neurosci., vol. 12, p. 193, Jul. 2018, doi: 10.3389/FNCEL.2018.00193.

[31].       M. Colonna and O. Butovsky, (2017). “Microglia Function in the Central Nervous System During Health and Neurodegeneration,” Annu. Rev. Immunol., vol. 35, p. 441, Apr. 2017, doi: 10.1146/ANNUREV-IMMUNOL-051116-052358.

[32].       M. C. Dias, J. A. Mapunda, M. Vladymyrov, and B. Engelhardt, (2019). “Structure and Junctional Complexes of Endothelial, Epithelial and Glial Brain Barriers,” International Journal of Molecular Sciences 2019, Vol. 20, Page 5372, vol. 20, no. 21, p. 5372, Oct. 2019, doi: 10.3390/IJMS20215372.

[33].       X. Shen, H. Li, B. Zhang, Y. Li, and Z. Zhu, (2025). “Targeting Transferrin Receptor 1 for Enhancing Drug Delivery Through the Blood–Brain Barrier for Alzheimer’s Disease,” Int. J. Mol. Sci., vol. 26, no. 19, p. 9793, Oct. 2025, doi: 10.3390/IJMS26199793.

[34].       Yang WM, Jung KJ, Lee MO, Lee YS, Lee YH, Nakagawa S, Niwa M, Cho SS, Kim DW. (2011). Transient expression of iron transport proteins in the capillary of the developing rat brain. Cell Mol Neurobiol. 2011 Jan;31(1):93-9. doi: 10.1007/s10571-010-9558-0. PMID: 21061168; PMCID: PMC11498480.

[35].       H. Baghirov, (2025). “Mechanisms of receptor-mediated transcytosis at the blood-brain barrier,” Journal of Controlled Release, vol. 381, p. 113595, May 2025, doi: 10.1016/J.JCONREL.2025.113595.

[36].       K. M. Mayle, A. M. Le, and D. T. Kamei, (2011). “The Intracellular Trafficking Pathway of Transferrin,” Biochim. Biophys. Acta, vol. 1820, no. 3, p. 264, Mar. 2011, doi: 10.1016/J.BBAGEN.2011.09.009.

[37].       Z. D. Zhou and E. K. Tan, (2017). “Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases,” Mol. Neurodegener., vol. 12, no. 1, p. 75, Oct. 2017, doi: 10.1186/S13024-017-0218-4.

[38].       Kochman U, Sitka H, Kuźniar J, Czaja M, Kozubek P, Beszłej JA, Leszek J. (2025). Targeted Nanoparticles for Drug Delivery Across the Blood-Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review. Mol Neurobiol. 2025 Nov 19;63(1):75. doi: 10.1007/s12035-025-05417-z. PMID: 41254247; PMCID: PMC12627166.

[39].       Y. Wu, Y. Qian, W. Peng, and X. Qi, (2023). “Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells,” PeerJ, vol. 11, p. e15571, 2023, doi: 10.7717/PEERJ.15571.

[40].       C. Li, L. Zhou, and X. Yin, (2024). “Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases,” Front. Pharmacol., vol. 15, p. 1342181, Mar. 2024, doi: 10.3389/FPHAR.2024.1342181/FULL.

[41].       T. Koneru, E. McCord, S. Pawar, K. Tatiparti, S. Sau, and A. K. Iyer, (2021). “Transferrin: Biology and Use in Receptor-Targeted Nanotherapy of Gliomas,” ACS Omega, vol. 6, no. 13, p. 8727, Apr. 2021, doi: 10.1021/ACSOMEGA.0C05848.

[42].       M. Kawamoto, M. Kohno, T. Horibe, and K. Kawakami, (2013). “Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent,” Cancer Chemother. Pharmacol., vol. 71, no. 3, pp. 799–807, Mar. 2013, doi: 10.1007/S00280-013-2074-4.

[43].       P. K. Kulabhusan, B. Hussain, and M. Yüce, (2020). “Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents,” Pharmaceutics, vol. 12, no. 7, p. 646, Jul. 2020, doi: 10.3390/PHARMACEUTICS12070646.

[44].       J. Zheng, Y. Sun, Y. Shen, and Z. Zhou, (2025). “Surface engineering of nanoparticles for precision medicine,” Precision Medicine and Engineering, vol. 2, no. 3, p. 100037, Sep. 2025, doi: 10.1016/J.PREME.2025.100037.

[45].       S. Yazdani, M. Mozaffarian, G. Pazuki, and N. Hadidi, (2026). “Artificial intelligence-assisted design and optimization of stimuli-responsive nanocarriers for smart drug delivery,” Mater. Today Bio, vol. 38, p. 103153, Jun. 2026, doi: 10.1016/J.MTBIO.2026.103153.

[46].       Z. Jin, L. Piao, G. Sun, C. Lv, Y. Jing, and R. Jin, (2020). “Dual functional nanoparticles efficiently across the blood–brain barrier to combat glioblastoma via simultaneously inhibit the PI3K pathway and NKG2A axis,” J. Drug Target., vol. 29, no. 3, pp. 323–335, 2020, doi: 10.1080/1061186X.2020.1841214.

[47].       C. Liu, J. Liu, Y. Y. Wang, S. F. Xu, and L. M. Yu, (2025). “APOE Lipoprotein Particles: Pathophysiology, Therapy, and the Crosstalk in Alzheimer’s Disease and Cardiovascular Disease,” Mol. Neurobiol., vol. 63, no. 1, p. 325, Jan. 2025, doi: 10.1007/S12035-025-05629-3.

[48].       A. P. Sagare, R. Deane, and B. V. Zlokovic, (2012). “Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities,” Pharmacol. Ther., vol. 136, no. 1, p. 94, Oct. 2012, doi: 10.1016/J.PHARMTHERA.2012.07.008.

[49].       E. Blázquez, E. Velázquez, V. Hurtado-Carneiro, and J. M. Ruiz-Albusac, (2014). “Insulin in the Brain: Its Pathophysiological Implications for States Related with Central Insulin Resistance, Type 2 Diabetes and Alzheimer’s Disease,” Front. Endocrinol. (Lausanne)., vol. 5, no. OCT, p. 161, 2014, doi: 10.3389/FENDO.2014.00161.

[50].       Z. Liu, T. Xiao, and H. Liu, (2023). “Leptin signaling and its central role in energy homeostasis,” Front. Neurosci., vol. 17, p. 1238528, 2023, doi: 10.3389/FNINS.2023.1238528.

[51].       A. S. Vallés and F. J. Barrantes, (2023). “Nicotinic Acetylcholine Receptor Dysfunction in Addiction and in Some Neurodegenerative and Neuropsychiatric Diseases,” Cells, vol. 12, no. 16, p. 2051, Aug. 2023, doi: 10.3390/CELLS12162051.

[52].       S. Liu, (2009). “Radiolabeled Cyclic RGD Peptides as Integrin αvβ3-Targeted Radiotracers: Maximizing Binding Affinity via Bivalency,” Bioconjug. Chem., vol. 20, no. 12, p. 2199, Dec. 2009, doi: 10.1021/BC900167C.

[53].       M. Westphal, C. L. Maire, and K. Lamszus, (2017). “EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise,” CNS Drugs, vol. 31, no. 9, p. 723, Sep. 2017, doi: 10.1007/S40263-017-0456-6.

[54].       N. Chegeni, F. Kadivar, and P. Saraei, (2025). “Folic Acid, Folate Conjugates and Folate Receptors: Novel Applications in Imaging of Cancer and Inflammation-Related Conditions,” Cancer Manag. Res., vol. 17, p. 2821, 2025, doi: 10.2147/CMAR.S549662.

[55].       Y. Kim and S. Kumar, (2014). “CD44-mediated Adhesion to Hyaluronic Acid Contributes to Mechanosensing and Invasive Motility,” Mol. Cancer Res., vol. 12, no. 10, p. 1416, Oct. 2014, doi: 10.1158/1541-7786.MCR-13-0629.

[56].       N. Iturrioz-Rodríguez, R. Bertorelli, and G. Ciofani, (2020). “Lipid-Based Nanocarriers for The Treatment of Glioblastoma,” Adv. Nanobiomed Res., vol. 1, no. 2, p. 2000054, Feb. 2020, doi: 10.1002/ANBR.202000054.

[57].       Ahmed, S., Mujahid, M. H., Kour, M., Fatima, S., Ahamad, S., Mishra, S. K., Bhat, A. R., Abu-Rayyan, A., & Tebeje, B. A. (2026). Molecular design and therapeutic applications of polymeric nanoparticles for drug delivery: A comprehensive review. Results in Chemistry, 28, 103459. https://doi.org/https://doi.org/10.1016/j.rechem.2026.103459

[58].       P. Kawak, N. M. A. Sawaftah, W. G. Pitt, and G. A. Husseini, (2023). “Transferrin-Targeted Liposomes in Glioblastoma Therapy: A Review,” Int. J. Mol. Sci., vol. 24, no. 17, p. 13262, Sep. 2023, doi: 10.3390/IJMS241713262.

[59].       N. Iturrioz-Rodríguez, N. Sampron, and A. Matheu, (2023). “Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment,” Theranostics, vol. 13, no. 9, p. 2734, 2023, doi: 10.7150/THNO.82005.

[60].       Y. Mo and L. Y. Lim, (2005). “Paclitaxel-loaded PLGA nanoparticles: Potentiation of anticancer activity by surface conjugation with wheat germ agglutinin,” Journal of Controlled Release, vol. 108, no. 2–3, pp. 244–262, Nov. 2005, doi: 10.1016/J.JCONREL.2005.08.013.

[61].       M. Damani, N. Nilawar, M. Momin, R. S. Ningthoujham, and T. Khan, (2025). “Nanoparticles assisted drug delivery for effective management of Glioblastoma,” Next Nanotechnology, vol. 7, p. 100137, Jan. 2025, doi: 10.1016/J.NXNANO.2025.100137.

[62].       Satapathy, M.K.; Yen, T.-L.; Jan, J.-S.; Tang, R.-D.; Wang, J.-Y.; Taliyan, R.; Yang, C.-H. (2021). Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB. Pharmaceutics 2021, 13, 1183. https://doi.org/10.3390/pharmaceutics13081183

[63].       J. Emami, M. Rezazadeh, H. Sadeghi, and K. Khadivar, (2017). “Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design,” Pharm. Dev. Technol., vol. 22, no. 3, pp. 370–382, Apr. 2017, doi: 10.1080/10837450.2016.1189933.

[64].       C. L. Waite and C. M. Roth, (2009). “PAMAM-RGD Conjugates Enhance siRNA Delivery Through a Multicellular Spheroid Model of Malignant Glioma,” Bioconjug. Chem., vol. 20, no. 10, pp. 1908–1916, Oct. 2009, doi: 10.1021/BC900228M.

[65].       Amaral, M. N., Kumar, P., Faísca, P., Ferreira, H. A., Coelho, J. M. P., Gaspar, M. M., & Reis, C. P. (2025). Gold nanoparticle-mediated photothermal therapy: Expanding the frontiers of cancer treatment and theragnostics. Biomedicine & Pharmacotherapy, 190, 118399. https://doi.org/https://doi.org/10.1016/j.biopha.2025.118399

[66].       Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P. (2023). Magnetic iron oxide nanoparticles for brain imaging and drug delivery. Advanced Drug Delivery Reviews, 197, 114822. https://doi.org/https://doi.org/10.1016/j.addr.2023.114822

[67].       A. M. Gharehbaba, F. Soltanmohammadi, M. Eskandani, and K. Adibkia, (2026). “Emerging roles of mesoporous silica nanoparticles in personalized medicine: revolutionizing therapy and diagnosis — a comprehensive review,” Results in Engineering, vol. 30, p. 110396, Jun. 2026, doi: 10.1016/J.RINENG.2026.110396.

[68].       Kawak, P.; Sawaftah, N.M.A.; Pitt, W.G.; Husseini, G.A. (2023). Transferrin-Targeted Liposomes in Glioblastoma Therapy: A Review. Int. J. Mol. Sci. 2023, 24, 13262. https://doi.org/10.3390/ijms241713262

[69].       Choudhury, H., Pandey, M., Chin, P.X. (2018). Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv. and Transl. Res. 8, 1545–1563. https://doi.org/10.1007/s13346-018-0552-2

[70].       S. Messina, C. Zuchegna, and M. Bruzzi, (2025). “Chemotherapeutic nanoparticles for glioblastoma,” Front. Oncol., vol. 15, p. 1641752, 2025, doi: 10.3389/FONC.2025.1641752.

[71].       Begagić, E.; Pugonja, R.; Bečulić, H.; Čeliković, A.; Tandir Lihić, L.; Kadić Vukas, S.; Čejvan, L.; Skomorac, R.; Selimović, E.; Jaganjac, B.; (2023).. Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings. Brain Sci. 2023, 13, 1602. https://doi.org/10.3390/brainsci13111602

[72].       F. Hanif, K. Muzaffar, K. Perveen, S. M. Malhi, and S. U. Simjee, (2017) “Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment,” Asian Pacific Journal of Cancer Prevention, vol. 18, no. 1, pp. 3–9, 2017, doi: 10.22034/APJCP.2017.18.1.3.

[73].       E. L. Lozada-Delgado, N. Grafals-Ruiz, and P. E. Vivas-Mejía, (2017). “RNA Interference for Glioblastoma therapy: Innovation ladder from the bench to clinical trials,” Life Sci., vol. 188, p. 26, Nov. 2017, doi: 10.1016/J.LFS.2017.08.027.

[74].       Romero-Ben, E., Goswami, U., Soto-Cruz, J., Mansoori-Kermani, A., Mishra, D., Martin-Saldaña, S., Muñoz-Ugartemendia, J., Sosnik, A., Calderón, M., Beloqui, A., & Larrañaga, A. (2025). Polymer-based nanocarriers to transport therapeutic biomacromolecules across the blood-brain barrier. Acta Biomaterialia, 196, 17–49. https://doi.org/https://doi.org/10.1016/j.actbio.2025.02.065

[75].       B. Majc, M. Novak, N. K. Jerala, A. Jewett, and B. Breznik, (2021). “Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development,” Cells, vol. 10, no. 2, p. 265, Feb. 2021, doi: 10.3390/CELLS10020265.

[76].       Fekrirad, Z.; Barzegar Behrooz, A.; Ghaemi, S.; Khosrojerdi, A.; Zarepour, A.; Zarrabi, A.; Arefian, E.; Ghavami, S. (2022). Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy. Cancers 2022, 14, 3698. https://doi.org/10.3390/cancers14153698

[77].       A. Zam, N. Rouatbi, A. A. Walters, and K. T. Al-Jamal, (2026). “Overcoming barriers and shaping the future: Challenges and innovations in nucleic acid therapies for Glioblastoma,” Adv. Drug Deliv. Rev., vol. 229, p. 115759, Feb. 2026, doi: 10.1016/J.ADDR.2025.115759.

[78].       J. Lee, M. K. Choi, and I. S. Song, (2023). “Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting,” Pharmaceuticals, vol. 16, no. 6, p. 802, Jun. 2023, doi: 10.3390/PH16060802.

[79].       P. S. Waghmare, A. R. Chabukswar, K. G. Raut, B. Gaikwad-Pawar, and S. C. Jagdale, (2024) “Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy,” Open Exploration 2019 5:4, vol. 5, no. 4, pp. 513–529, Jul. 2024, doi: 10.37349/EMED.2024.00236.

[80].       N. E. El-hefnawy, M. M. Youssef, H. Abol-Enein, and R. A. Gabal, (2025). “mTOR pathway targeted inhibition via Rapamycin-loaded PLGA nanoparticles for enhanced bladder cancer therapy,” Scientific Reports 2025 15:1, vol. 15, no. 1, pp. 23138-, Jul. 2025, doi: 10.1038/s41598-025-06965-z.

[81].       L. Cai, X. Xu, and W. Chen, (2022). “The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems,” Pharmaceutics, vol. 14, no. 8, p. 1647, Aug. 2022, doi: 10.3390/PHARMACEUTICS14081647.

[82].       P. Wang, J. Gong, Y. Xu, and X. Xia, (2026). “siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy,” Int. J. Mol. Sci., vol. 27, no. 7, p. 3032, Apr. 2026, doi: 10.3390/IJMS27073032.

[83].       S. Pandey and P. Yadav, (2025). “Exploring the therapeutic potential of microRNAs: targeted gene regulation strategies for enhanced cancer therapy,” Journal of Genetic Engineering and Biotechnology, vol. 23, no. 4, p. 100556, Dec. 2025, doi: 10.1016/J.JGEB.2025.100556.

[84].       K. Youn, S. Oh, H. Gil, Y. Choi, G. Keum, and E. K. Bang, (2025). “Delivery strategies of messenger RNA therapeutics for brain disorders,” Bull. Korean Chem. Soc., vol. 46, no. 12, pp. 1186–1204, Dec. 2025, doi: 10.1002/BKCS.70083;PAGE:STRING:ARTICLE/CHAPTER.

[85].       P. Kazemian, S. Y. Yu, S. B. Thomson, A. Birkenshaw, B. R. Leavitt, and C. J. D. Ross, (2022). “Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components,” Mol. Pharm., vol. 19, no. 6, pp. 1669–1686, Jun. 2022, doi: 10.1021/ACS.MOLPHARMACEUT.1C00916.

[86].       X. Yu, C. Fang, K. Zhang, and C. Su, (2022). “Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment,” Pharmaceutics, vol. 14, no. 8, p. 1581, Aug. 2022, doi: 10.3390/PHARMACEUTICS14081581.

[87].       Fan S, Han H, Yan Z, Lu Y, He B, Zhang Q. (2023). Lipid-based nanoparticles for cancer immunotherapy. Med Rev (2021). 2023 Aug 17;3(3):230-269. doi: 10.1515/mr-2023-0020. PMID: 37789955; PMCID: PMC10542882.

[88].       H. Zhou, Y. Shi, Y. Wang, and G. Bai, (2026). “Exosome-based vaccines in cancer immunotherapy: antitumor mechanisms, engineering strategies, and challenges,” J. Cancer Res. Clin. Oncol., vol. 152, no. 3, p. 68, Mar. 2026, doi: 10.1007/S00432-026-06435-7.

[89].       S. M. S. Mousavi-Kiasary (2025). “Synergistic Cancer Therapies Enhanced by Nanoparticles: Advancing Nanomedicine Through Multimodal Strategies,” Pharmaceutics, vol. 17, no. 6, p. 682, Jun. 2025, doi: 10.3390/PHARMACEUTICS17060682.

[90].       Ruiz-Molina, D.; Mao, X.; Alfonso-Triguero, P.; Lorenzo, J.; Bruna, J.; Yuste, V.J.; Candiota, A.P.; Novio, F. (2022). Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? Cancers 2022, 14, 4960. https://doi.org/10.3390/cancers14194960

[91].       Balzer, V., Poc, P., Puris, E., Martin, S., Aliasgari, M., Auriola, S., & Fricker, G. (2022). Re-evaluation of the hCMEC/D3 based in vitro BBB model for ABC transporter studies. European Journal of Pharmaceutics and Biopharmaceutics, 173, 12–21. https://doi.org/https://doi.org/10.1016/j.ejpb.2022.02.017

[92].       Y. Ju, H. Guo, M. Edman, and S. F. Hamm-Alvarez, (2020). “Application of advances in endocytosis and membrane trafficking to drug delivery,” Adv. Drug Deliv. Rev., vol. 157, p. 118, Jan. 2020, doi: 10.1016/J.ADDR.2020.07.026.

[93].       C. Ferreira, B. Sarmento, and C. Martins, (2025). “In vitro models of the interplay between glioblastoma and blood–brain barrier for stratifying drug efficacy,” Adv. Drug Deliv. Rev., vol. 227, p. 115702, Dec. 2025, doi: 10.1016/J.ADDR.2025.115702.

[94].       Raza, K., Kumar, P., Kumar, N., & Malik, R. (2017). 9 - Pharmacokinetics and biodistribution of the nanoparticles (S. Nimesh, R. Chandra, & N. B. T.-A. in N. for the D. of T. N. A. Gupta (eds.); pp. 165–186). Woodhead Publishing. https://doi.org/https://doi.org/10.1016/B978-0-08-100557-6.00009-2

[95].       H. Ding and F. Wu, (2012). “Image Guided Biodistribution and Pharmacokinetic Studies of Theranostics,” Theranostics, vol. 2, no. 11, p. 1040, 2012, doi: 10.7150/THNO.4652.

[96].       Huang A, Jiang Z, Liang Z, Tang N, Liu J, Yu XA, Wang B, Wang X. (2026). Biological Safety Analysis of Nanoparticles: Exploring Toxicity, Mechanisms, and Safety Factors for Pharmaceuticals. Int J Nanomedicine. 2026 May 25;21:602693. doi: 10.2147/IJN.S602693. PMID: 42220973; PMCID: PMC13220827.

[97].       Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K, Liou JP. (2022). Glioblastoma: Current Status, Emerging Targets, and Recent Advances. J Med Chem. 2022 Jul 14;65(13):8596-8685. doi: 10.1021/acs.jmedchem.1c01946. Epub 2022 Jul 5. PMID: 35786935; PMCID: PMC9297300.

[98].       M. L. Goodenberger and R. B. Jenkins, (2012). “Genetics of adult glioma,” Cancer Genet., vol. 205, no. 12, pp. 613–621, Dec. 2012, doi: 10.1016/J.CANCERGEN.2012.10.009.

[99].       T. Koneru, E. McCord, S. Pawar, K. Tatiparti, S. Sau, and A. K. Iyer, (2021). “Transferrin: Biology and Use in Receptor-Targeted Nanotherapy of Gliomas,” ACS Omega, vol. 6, no. 13, pp. 8727–8733, Apr. 2021, doi: 10.1021/ACSOMEGA.0C05848.

[100].    H. K. Rachamala, (2025). “Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons,” Pharmaceutics 2025, Vol. 17, Page 1315, vol. 17, no. 10, p. 1315, Oct. 2025, doi: 10.3390/PHARMACEUTICS17101315.

[101].    Voth, B., Nagasawa, D. T., Pelargos, P. E., Chung, L. K., Ung, N., Gopen, Q., Tenn, S., Kamei, D. T., & Yang, I. (2015). Transferrin receptors and glioblastoma multiforme: Current findings and potential for treatment. Journal of Clinical Neuroscience, 22(7), 1071–1076. https://doi.org/https://doi.org/10.1016/j.jocn.2015.02.002

[102].    V. Kurawattimath, B. Wilson, and K. M. Geetha, (2023). “Nanoparticle-based drug delivery across the blood-brain barrier for treating malignant brain glioma,” OpenNano, vol. 10, p. 100128, Mar. 2023, doi: 10.1016/J.ONANO.2023.100128.

[103].    Duan M, Cao R, Yang Y, Chen X, Liu L, Ren B, Wang L, Goh BC. (2024). Blood-Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges. Cancers (Basel). 2024 Sep 27;16(19):3300. doi: 10.3390/cancers16193300. PMID: 39409919; PMCID: PMC11475686.

[104].    C. Lucchi, R. Meanti, and H.-M. Yang, (2025). “Overcoming the Blood–Brain Barrier: Advanced Strategies in Targeted Drug Delivery for Neurodegenerative Diseases,” Pharmaceutics 2025, Vol. 17, Page 1041, vol. 17, no. 8, p. 1041, Aug. 2025, doi: 10.3390/PHARMACEUTICS17081041.

[105].    Guo, X., Liu, G., Liu, Y. (2026). Nanomedicine-based therapeutic strategies for cerebral ischemia–reperfusion injury: from blood–brain barrier penetration to precision targeting. Eur J Med Res 31, 514. https://doi.org/10.1186/s40001-026-04073-w

[106].    I. Csóka, R. Ismail, O. Jójárt-Laczkovich, and E. Pallagi, (2021). “Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development,” Curr. Med. Chem., vol. 28, no. 36, pp. 7461–7476, Apr. 2021, doi: 10.2174/0929867328666210406115529.

[107].    S. L. Kardani, (2024). “Nanocarrier-based formulations: Regulatory Challenges, Ethical and Safety Considerations in Pharmaceuticals,” Asian J. Pharm., vol. 18, no. 02, Jun. 2024, doi: 10.22377/AJP.V18I02.5444.

[108].    I. S. Sami and J. U. Ahamed, (2026). “Synergistic drug homing for glioblastoma: Integrating biomimetic nanocarriers with MR-guided focused ultrasound across the blood-brain barrier,” Mater. Today Adv., vol. 31, p. 100859, Aug. 2026, doi: 10.1016/J.MTADV.2026.100859.

[109].    K. Rawojć, M. M. Ahmed, A. Mukhtiar, M. Łukowiak, and K. Kisielewicz, (2025). “Nanomedicine-Enhanced Radiotherapy for Glioblastoma: Advances in Targeted Therapy and Adaptive Treatment Strategies,” Pharmaceutics, vol. 17, no. 4, p. 508, Apr. 2025, doi: 10.3390/PHARMACEUTICS17040508.

[110].    H. J. Liu and P. Xu, (2022). “Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor,” Adv. Drug Deliv. Rev., vol. 191, p. 114619, Dec. 2022, doi: 10.1016/J.ADDR.2022.114619.

[111].    Nicola, J. P., & LaRocca, C. J. (2023). Sodium iodide symporter-targeted gene therapy in glioblastoma. Molecular Therapy - Oncolytics, 28, 44–45. https://doi.org/https://doi.org/10.1016/j.omto.2022.12.004

[112].    E. Mastrantuono, M. Ghibaudi, D. Matias, and G. Battaglia, (2024). “The multifaceted therapeutical role of low‐density lipoprotein receptor family in high‐grade glioma,” Mol. Oncol., vol. 18, no. 12, p. 2966, Dec. 2024, doi: 10.1002/1878-0261.13730.

[113].    W. Echavidre, V. Picco, M. Faraggi, and C. Montemagno, (2022). “Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?,” Pharmaceutics, vol. 14, no. 5, p. 1053, May 2022, doi: 10.3390/PHARMACEUTICS14051053.

[114].    N. I. Okafor, N. Igbokwe, H. Onohuean, M. Faya, and Y. E. Choonara, (2026). “Artificial Intelligence-Driven Development and Characterization of Nanomedicine,” BioNanoScience 2026 16:4, vol. 16, no. 4, pp. 255-, Mar. 2026, doi: 10.1007/S12668-026-02476-X.

[115].    W. C. Chou, A. Canchola, F. Zhang, and Z. Lin, (2025). “Machine Learning and Artificial Intelligence in Nanomedicine,” Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., vol. 17, no. 4, p. e70027, Jul. 2025, doi: 10.1002/WNAN.70027.

[116].    Wu, D., Zhao, J., Xu, T., Xiang, H., Zhao, B., Gao, L., & Chen, Y. (2024). Glioma nanomedicine: Design, fabrication and theranostic application. Coordination Chemistry Reviews, 505, 215696. https://doi.org/https://doi.org/10.1016/j.ccr.2024.215696

[117].    S. Sharon, G. Mainkar, and L. Zangi, (2026). “Personalized Nanomedicine: Integrating Molecular Stratification with Engineered Delivery Systems,” Journal of Nanotheranostics 2026, Vol. 7, Page 9, vol. 7, no. 2, p. 9, Apr. 2026, doi: 10.3390/JNT7020009.

[118].    Y. Zorkina, O. Abramova, E. Zubkov, O. Gurina, and V. Ushakova, (2026). “Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions,” International Journal of Molecular Sciences 2026, Vol. 27, Page 3560, vol. 27, no. 8, p. 3560, Apr. 2026, doi: 10.3390/IJMS27083560.

[119].    Khoramipour, M., Chegeni, M. M., Moradbeygi, F., Najafi, F., Kabarkouhi, Z., Poodeh, S. H., Larijani, S. F., Ghaemi, A., Jevinani, H. N., Goodarzi, A., Beram, F. M., Moeinzadeh, A., Moghaddam, N. A., Farmani, A. R., & Bernkop-Schnürch, A. (2026). Gold nanoparticles as a versatile theranostic platform in oncology: A comprehensive point of view on synthesis, properties, functionalization, and clinical translation. Colloid and Interface Science Communications, 72, 100880. https://doi.org/https://doi.org/10.1016/j.colcom.2026.100880

[120].    Zeeshan, M., Hu, J., Mao, C.-X., Danish, A., Xiong, Y., Irshad, M. S., Dao, V.-D., & Liu, Z. (2025). Nanomaterial-enabled drug delivery systems for circadian medicine: bridging direct rhythm modulation and chronotherapy. RSC Advances, 15(38), 31981–32008. https://doi.org/https://doi.org/10.1039/d5ra04137f

[121].    Khalid, Q., Rehman, M., Wang, Y.-F., & Liang, X.-J. (2025). Recent advances in nanopharmaceutical strategies for cancer treatment. Biochemical and Biophysical Research Communications, 777, 152249. https://doi.org/https://doi.org/10.1016/j.bbrc.2025.152249

[122].    M. J. Ramalho, J. A. Loureiro, M. A. N. Coelho, and M. C. Pereira, (2022). “Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma,” Pharmaceutics, vol. 14, no. 2, p. 279, Feb. 2022, doi: 10.3390/PHARMACEUTICS14020279.

[123].    C. Chin, E. S. Lunking, M. De La Fuente, and N. G. Ayad, (2018). “Immunotherapy and epigenetic pathway modulation in glioblastoma multiforme,” Front. Oncol., vol. 8, no. NOV, 2018, doi: 10.3389/FONC.2018.00521.

[124].    Bahuguna, R., Rehman, F., Awasthi, R., Babu, K. R., Akhter, M. H., Begum, M. Y., Kumar, D., Gupta, S. M., Singh, S., & Singh, P. A. (2026). Frontiers and challenges in brain drug delivery: Emerging nanotechnology approaches to overcome the blood-brain barrier for neurodegenerative disease treatment. Journal of Drug Delivery Science and Technology, 115, 107759. https://doi.org/https://doi.org/10.1016/j.jddst.2025.107759

[125].    Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, He H, Yang VC, Huang Y. (2016). Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy. ACS Nano. 2016 Nov 22;10(11):9999-10012. doi: 10.1021/acsnano.6b04268. Epub 2016 Nov 8. PMID: 27934069.

[126].    J. Liu, Y. Y. Liu, C. S. Li, A. Cao, and H. Wang, (2023). “Exocytosis of Nanoparticles: A Comprehensive Review,” Nanomaterials 2023, Vol. 13, Page 2215, vol. 13, no. 15, p. 2215, Jul. 2023, doi: 10.3390/NANO13152215.

[127].    K. M. Mayle, A. M. Le, and D. T. Kamei, (2011). “The Intracellular Trafficking Pathway of Transferrin,” Biochim. Biophys. Acta, vol. 1820, no. 3, p. 264, Mar. 2011, doi: 10.1016/J.BBAGEN.2011.09.009.

[128].    Pouyan, A., Ghorbanlo, M., Eslami, M. (2025). Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer 24, 58. https://doi.org/10.1186/s12943-025-02267-0

[129].    N. Rabah, F. E. Ait Mohand, and N. Kravchenko-Balasha, (2023). “Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers,” Int. J. Mol. Sci., vol. 24, no. 18, p. 14256, Sep. 2023, doi: 10.3390/IJMS241814256.

[130].    Zhang, P., Xiao, Y., Sun, X., Lin, X., Koo, S., Yaremenko, A. V, Qin, D., Kong, N., Farokhzad, O. C., & Tao, W. (2023). Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects. Med, 4(3), 147–167. https://doi.org/https://doi.org/10.1016/j.medj.2022.12.001

[131].    Y. Liu, Y. Zhang, H. Li, and T. Y. Hu, (2025). “Recent advances in the bench-to-bedside translation of cancer nanomedicines,” Acta Pharm. Sin. B, vol. 15, no. 1, pp. 97–122, Jan. 2025, doi: 10.1016/J.APSB.2024.12.007.

[132].    Wang, B., Hu, S., Teng, Y. (2024). Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Sig Transduct Target Ther 9, 200. https://doi.org/10.1038/s41392-024-01889-y

[133].    N. Šamec, A. Zottel, A. V. Paska, and I. Jovčevska, (2020). “Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma,” Molecules, vol. 25, no. 3, p. 490, Jan. 2020, doi: 10.3390/MOLECULES25030490.